Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to HER2-positive Breast Cancer
Related studies linked through entity extraction aliases.
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer
- Status
- UNKNOWN
- Phase
- NA
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE3
Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
- Status
- TERMINATED
- Phase
- N/A
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- NA
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
- Status
- COMPLETED
- Phase
- PHASE2
Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
- Status
- TERMINATED
- Phase
- PHASE2